Singapore markets open in 3 hours 17 minutes
Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,180.74 +52.95 (+1.03%) Dow
38,852.27 +176.59 (+0.46%) Nasdaq
16,349.25 +192.92 (+1.19%) Bitcoin USD
63,459.12 -278.82 (-0.44%) CMC Crypto 200
1,364.74 +52.11 (+3.97%)
Ligand Pharmaceuticals Incorporated (LGND)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 73.90 |
| Open | 74.05 |
| Bid | 72.60 x 100 |
| Ask | 73.08 x 100 |
| Day's range | 72.62 - 74.70 |
| 52-week range | 49.24 - 94.57 |
| Volume | |
| Avg. volume | 181,050 |
| Market cap | 1.308B |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | 24.04 |
| EPS (TTM) | 3.03 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 Jul 2010 |
| 1y target est | 116.80 |
Zacks5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
ZacksAgios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
ZacksBlueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
© 2024 Yahoo. All rights reserved.